<?xml version="1.0" encoding="UTF-8"?>
<ref id="B45-medicines-04-00034">
 <label>45.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Park</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Nam</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Yun</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Lee</surname>
    <given-names>S.G.</given-names>
   </name>
   <name>
    <surname>Jang</surname>
    <given-names>H.J.</given-names>
   </name>
   <name>
    <surname>Sethi</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Cho</surname>
    <given-names>S.K.</given-names>
   </name>
   <name>
    <surname>Ahn</surname>
    <given-names>K.S.</given-names>
   </name>
  </person-group>
  <article-title>Î²-caryophyllene oxide inhibits growth and induces apoptosis through the suppression of PI3K/AKT/mTOR/S6K1 pathways and ROS-mediated MAPKs activation</article-title>
  <source>Cancer Lett.</source>
  <year>2011</year>
  <volume>312</volume>
  <fpage>178</fpage>
  <lpage>188</lpage>
  <pub-id pub-id-type="doi">10.1016/j.canlet.2011.08.001</pub-id>
  <?supplied-pmid 21924548?>
  <pub-id pub-id-type="pmid">21924548</pub-id>
 </element-citation>
</ref>
